Iq-ai Ltd Share News (IQAI)

Iq-ai Ltd Information

Buy IQAI Shares
Add IQAI to Watchlist
Add IQAI to Alert

Share Price Information for Iq-ai Ltd (IQAI)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 1.40

Bid: 1.30

Ask: 1.50

Change: 0.00 (0.00%)

Spread: 0.20 (15.385%)

Open: 1.40

High: 1.40

Low: 1.40

Prev. Close: 1.40

Last checked at -

IN BRIEF: IQ-AI shares rise with submission of application to US FDA

Tue, 31st May 2022 13:26

IQ-AI Ltd - Jersey-based medical services firm - Says subsidiary Imaging Biometrics LLC submits 510(k) application to US Food & Drug Administration for IB Zero G, an artificial intelligence software that eliminates the need for gadolinium-based contrast agents in routine magnetic imagining exams. "The FDA 510(k) submission is the first step in potentially transforming the global gadolinium-based contrast agent market and introducing a paradigm shift in radiology departments," company says.

Current stock price: 4.35 pence, up 8.8% on Tuesday

12-month change: down 42%

By Abby Amoakuh; abbyamoakuh@alliancenews.com

More News

3 May 2022 16:36

IQ-AI imaging technology gets vote of confidence in US study

(Alliance News) - IQ-AI Ltd unit Imaging Biometrics on Tuesday said a study concluded its imaging technology was successful in identifying tumours.

28 Apr 2022 19:25

TRADING UPDATES: Impellam's first quarter beats pre-virus levels

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

9 Mar 2022 20:30

IN BRIEF: IQ-AI opens oral gallium malotate trial for enrolment

IQ-AI Ltd - Jersey-based medical services firm - Says phase one clinical trial for oral gallium maltolate is open for enrolment. Patient recruitment in the trial is underway and potential volunteers that meet the inclusion criteria have already been identified, it notes. Phase one dose escalation study is designed to determine the optimal dose of GaM that can be administered safely. It is the first-in-human clinical trial for an oral form of GaM to be used in patients with high-grade brain tumours, it adds.

11 Nov 2021 19:43